Provided by Tiger Fintech (Singapore) Pte. Ltd.

Atea Pharmaceuticals, Inc.

2.87
+0.0000
Volume:134.56K
Turnover:383.53K
Market Cap:245.46M
PE:-1.44
High:2.94
Open:2.80
Low:2.80
Close:2.87
Loading ...

Atea Pharmaceuticals Inc - Phase 2 Study Achieves 98% Svr12 After 8 Weeks

THOMSON REUTERS
·
04 Dec 2024

Atea Pharmaceuticals Inc - No Drug-Related Serious Adverse Events or Treatment Discontinuations

THOMSON REUTERS
·
04 Dec 2024

Atea Pharmaceuticals Announces Positive Results From Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (Hcv)

THOMSON REUTERS
·
04 Dec 2024

Atea Pharmaceuticals Inc - Regimen Generally Safe and Well-Tolerated

THOMSON REUTERS
·
04 Dec 2024

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

GlobeNewswire
·
04 Dec 2024

Atea Pharmaceuticals to Present and Provide a Business Update at the 7TH Annual Evercore Healthconx Conference

THOMSON REUTERS
·
26 Nov 2024

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

GlobeNewswire
·
26 Nov 2024

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Zacks
·
22 Nov 2024

Atea Pharmaceuticals presents three HCV poster presentations at AASLD

TIPRANKS
·
16 Nov 2024

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at Aasld’s the Liver Meeting 2024

THOMSON REUTERS
·
16 Nov 2024

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

GlobeNewswire
·
16 Nov 2024

Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

GuruFocus.com
·
12 Nov 2024

Atea Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

BRIEF-Atea Pharmaceuticals Inc Files For Mixed Shelf Of Up To $500 Million - SEC Filing

Reuters
·
08 Nov 2024

Atea Pharmaceuticals Q3 2024 GAAP EPS $(0.37) Beats $(0.49) Estimate

Benzinga
·
08 Nov 2024

Atea Pharmaceuticals Inc Files for Mixed Shelf of up to $500 Mln - SEC Filing

THOMSON REUTERS
·
08 Nov 2024

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

GlobeNewswire
·
31 Oct 2024

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

GlobeNewswire
·
30 Oct 2024